Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML0422

Sigma-Aldrich

Istradefylline

≥98% (HPLC)

Sinônimo(s):

(E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine, 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

5 MG
R$ 780,00
25 MG
R$ 2.903,00

R$ 780,00

Check Cart for Availability
Solicite uma grande encomenda
Todas as fotos(1)

Selecione um tamanho

Alterar visualização
5 MG
R$ 780,00
25 MG
R$ 2.903,00

About This Item

Fórmula empírica (Notação de Hill):
C20H24N4O4
Número CAS:
155270-99-8
Peso molecular:
384.43
Número MDL:
MFCD00928421
Código UNSPSC:
12352200
ID de substância PubChem:
329825417
NACRES:
NA.77

R$ 780,00

Check Cart for Availability
Solicite uma grande encomenda

Nível de qualidade

100

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 5 mg/mL (clear solution)

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CCN1C(=O)N(CC)c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2C1=O

InChI

1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+

chave InChI

IQVRBWUUXZMOPW-PKNBQFBNSA-N

Informações sobre genes

human ... ADORA2A(135)

Ações bioquímicas/fisiológicas

Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist which has been investigated for use in Parkinson′s Disease.
Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist.

Características e benefícios

This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictogramas

Skull and crossbones
GHS06

Palavra indicadora

Danger

Frases de perigo

H301

Declarações de precaução

P264 - P270 - P301 + P310 - P405 - P501

Classificações de perigo

Acute Tox. 3 Oral

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000220772
0000218350
0000218351
0000220772
0000218351

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Peter Jenner
Expert opinion on investigational drugs, 14(6), 729-738 (2005-07-12)
Dopamine replacement therapy effectively treats the early motor symptoms of Parkinson's disease (PD). However, its association with the development of motor complications limits its usefulness in late stages of the disease. Adenosine A(2A) receptors are localised to the indirect striatal
Nikoletta Szabó et al.
Expert opinion on drug metabolism & toxicology, 7(4), 441-455 (2011-02-22)
Parkinson's disease (PD) is a progressive neurodegenerative disorder. To date, most of the currently available therapies in PD target the dopaminergic system and none of these therapeutic approaches have been proven to modify the course of the disease. To various
H H Fernandez et al.
Parkinsonism & related disorders, 16(1), 16-20 (2009-07-21)
6002-US-051 was a 12-week, double-blind study evaluating the safety and efficacy of istradefylline, a selective A(2A) adenosine receptor antagonist, as monotherapy in patients with Parkinson's disease (PD). Patients with Hoehn-Yahr stages 1-2.5 who had not received dopaminergic drugs in the
P Jenner et al.
Parkinsonism & related disorders, 15(6), 406-413 (2009-05-19)
Adenosine derived from the degradation of ATP/AMP functions as a signalling molecule in the nervous system through the occupation of A1, A2, and A3 adenosine receptors. Adenosine A(2A) receptors have a selective localization to the basal ganglia and specifically to
Robert A Hauser et al.
Movement disorders : official journal of the Movement Disorder Society, 23(15), 2177-2185 (2008-10-04)
The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW-6002) is an
Exibir todos os documentos relacionados

Artigos

Adenosine Receptors

We offers many products related to adenosine receptors for your research needs.

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica